Regeneron Pharmaceuticals, Inc.
$753.59
▲
0.83%
2026-04-22 10:12:13
www.regeneron.com
NMS: REGN
Explore Regeneron Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$79.36 B
Current Price
$753.59
52W High / Low
$821.11 / $476.49
Stock P/E
17.99
Book Value
$304.65
Dividend Yield
0.5%
ROCE
10.23%
ROE
14.86%
Face Value
—
EPS
$41.89
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
15,410
Beta
0.4
Debt / Equity
9.51
Current Ratio
4.13
Quick Ratio
3.39
Forward P/E
14.25
Price / Sales
5.52
Enterprise Value
$71.22 B
EV / EBITDA
16.77
EV / Revenue
4.96
Rating
Buy
Target Price
$874.48
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Meaningful dividend yield is available.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | vTv Therapeutics Inc. | $37.75 | — | $157.78 M | — | -39.41% | -78.94% | $44 / $14 | $5.19 |
| 2. | Terns Pharmaceuticals, Inc. | $52.74 | — | $6.09 B | — | -10.92% | -14.23% | $53.19 / $2.23 | $8.96 |
| 3. | Tyra Biosciences, Inc. | $34.37 | — | $1.92 B | — | -50.19% | -39.83% | $40.65 / $7.8 | $4.83 |
| 4. | YD Bio Ltd | $5.31 | — | $382.42 M | — | -22.15% | -42.69% | $31 / $5.12 | $4.57 |
| 5. | Ocular Therapeutix, Inc. | $9.52 | — | $2.09 B | — | -35.66% | -54.85% | $16.44 / $6.23 | $3.03 |
| 6. | CollPlant Biotechnologies Ltd. | $0.37 | — | $5.15 M | — | -141.54% | -1.18% | $4.98 / $0.27 | $0.47 |
| 7. | Rani Therapeutics Holdings, Inc. | $0.97 | — | $118.3 M | — | -83.37% | -1.82% | $3.87 / $0.39 | $0.34 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 3.88 B | 3.75 B | 3.68 B | 3.03 B | 3.79 B | — |
| Operating Profit | 898.6 M | 1.11 B | 1.08 B | 591.7 M | 990.2 M | — |
| Net Profit | 844.6 M | 1.46 B | 1.39 B | 808.7 M | 917.7 M | — |
| EPS in Rs | 8.13 | 14.05 | 13.39 | 7.78 | 8.83 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 14.34 B | 14.2 B | 13.12 B | 12.17 B |
| Operating Profit | 3.7 B | 3.99 B | 4.05 B | 4.74 B |
| Net Profit | 4.5 B | 4.41 B | 3.95 B | 4.34 B |
| EPS in Rs | 43.36 | 42.47 | 38.05 | 41.75 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 40.56 B | 37.76 B | 33.08 B | 29.21 B |
| Total Liabilities | 9.3 B | 8.41 B | 7.11 B | 6.55 B |
| Equity | 31.26 B | 29.35 B | 25.97 B | 22.66 B |
| Current Assets | 18.02 B | 18.66 B | 19.48 B | 15.88 B |
| Current Liabilities | 4.37 B | 3.94 B | 3.42 B | 3.14 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 4.98 B | 4.42 B | 4.59 B | 5.01 B |
| Investing CF | -629.1 M | -2.47 B | -3.19 B | -3.78 B |
| Financing CF | -3.72 B | -2.2 B | -1.79 B | -1.01 B |
| Free CF | 3.77 B | 3.54 B | 3.67 B | 3.4 B |
| Capex | -1.21 B | -881.6 M | -926.4 M | -1.62 B |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 8.27% | 7.76% | — | — |
| Earnings Growth % | 11.61% | -8.87% | — | — |
| Profit Margin % | 31.07% | 30.14% | 35.64% | — |
| Operating Margin % | 28.1% | 30.85% | 38.93% | — |
| Gross Margin % | 86.13% | 86.16% | 87.18% | — |
| EBITDA Margin % | 37.45% | 35.78% | 43.21% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-02-20 | $0.94 |
| 2025-11-20 | $0.88 |
| 2025-08-18 | $0.88 |
| 2025-05-20 | $0.88 |
| 2025-02-20 | $0.88 |
Stock Splits
No stock split history available.